Back to Search Start Over

Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD

Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD

Authors :
Breno de Alencar Araripe Falcão
Expedito E. Ribeiro
Bruno Moulin
Gustavo R. Morais
Rutao Wang
Masafumi Ono
Hironori Hara
Pedro A. Lemos
Fernanda Barbosa de Almeida Sampaio
Rodrigo Modolo
Norihiro Kogame
João Eduardo Prudêncio Tinoco
Hideyuki Kawashima
Yoshinobu Onuma
Fernando de Martino
George C. Meireles
Rafael Cavalcante
Carlos M. Campos
Patrícia O. Guimarães
Rogério S. Leite
Patrick W. Serruys
Source :
JACC: Cardiovascular Interventions. 13:2251-2262
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Objectives The aim of this study was to evaluate the hypothesis that prasugrel monotherapy following successful everolimus-eluting stent implantation is feasible and safe in patients with stable coronary artery disease (CAD). Background Recent studies have suggested that short dual-antiplatelet therapy strategies may provide an adequate balance between ischemic and bleeding risks. However, the complete omission of aspirin immediately after percutaneous coronary intervention (PCI) has not been tested so far. Methods The study was a multicenter, single-arm, open-label trial with a stopping rule based on the occurrence of definite stent thrombosis (if >3, trial enrollment would be terminated). Patients undergoing successful everolimus-eluting stent implantation for stable CAD with SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores Results From February 22, 2018, to May 7, 2019, 201 patients were enrolled. All patients underwent PCI for stable CAD. Overall, 98.5% of patients were adherent to prasugrel at 3-month follow-up. The primary ischemic and bleeding endpoints occurred in 1 patient (0.5%). No stent thrombosis events occurred. Conclusions Aspirin-free prasugrel monotherapy following successful everolimus-eluting stent implantation demonstrated feasibility and safety without any stent thrombosis in selected low-risk patients with stable CAD. These findings may help underpin larger randomized controlled studies to evaluate the aspirin-free strategy compared with traditional dual-antiplatelet therapy following PCI. (Acetyl Salicylic Elimination Trial: The ASET Pilot Study [ASET]; NCT03469856)

Details

ISSN :
19368798
Volume :
13
Database :
OpenAIRE
Journal :
JACC: Cardiovascular Interventions
Accession number :
edsair.doi...........fa5fb38d3464f9ac6b1c7b5ebd207b78
Full Text :
https://doi.org/10.1016/j.jcin.2020.06.023